- Conditions
- Skin Aging
- Interventions
- Sofwave, Sculptra
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 716
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Akron, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- PreDiabetes, Obesity
- Interventions
- High Carbohydrate Diet, Reduced Carbohydrate Diet
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
- Interventions
- Rituximab, Brentuximab Vedotin, Bendamustine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Rochester, Minnesota
- Conditions
- Small Cell Lung Cancer
- Interventions
- Vorinostat, Carboplatin, Etoposide
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- A Program of SUPPORT-D (dementia)
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Mantle Cell Lymphoma
- Interventions
- R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Valeda Light Delivery System
- Device
- Lead sponsor
- LumiThera, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- peripheral blood progenitor cells carrying MDR1
- Genetic
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Malignant Glioma, Glioblastoma Multiforme
- Interventions
- Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
- Biological
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Lung Cancer, Metastatic Lung Cancer
- Interventions
- Stereotactic Body Radiotherapy (SBRT)
- Radiation
- Lead sponsor
- The Netherlands Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Royal Oak, Michigan • Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
- Interventions
- Intravesical Gemcitabine and Docetaxel
- Drug
- Lead sponsor
- Michael A. O'Donnell
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Interventions
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6, FOLFIRI, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Kestrel Therapeutics, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more
- Conditions
- Bioavailability, B-cell Lymphoid Cancer
- Interventions
- Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cirrhosis, Liver, Portal Hypertension
- Interventions
- Enhanced Usual Care, Lactulose, Investigator recommended exercise, TeleTai-Chi (virtual)
- Behavioral · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Interventions
- ASP5834, panitumumab
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Interventions
- AU-007, Aldesleukin, Avelumab, Nivolumab
- Drug
- Lead sponsor
- Aulos Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
- Conditions
- No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
- Interventions
- Osteopathic Manipulative Treatment, Sham
- Other
- Lead sponsor
- Lake Erie College of Osteopathic Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Breast Cancer, Cancer of the Breast, Neoplasms, Breast
- Interventions
- Estrace, Anastrozole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Cyclophosphamide, Docetaxel
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana